ASH: Obinutuzumab Bests Rituximab in Patients With Relapsed Non-Hodgkin Lymphoma Cancer Network SAN DIEGO—Obinutuzumab (GA101) achieved higher response rates than rituximab in the first head-to-head trial of the two biologic agents in patients with relapsed non-Hodgkin lymphoma (NHL). ... ASH: Novel Antibody Promising in Lymphoma Roche's blood cancer antibody outperforms MabThera |
